Amphastar Pharma(AMPH): Outlook Hinges on Primatene and a Key ANDA Approval - Jefferies

November 9, 2016 8:36 AM EST
Get Alerts AMPH Hot Sheet
Price: $19.88 +1.17%

Rating Summary:
    4 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 18 | New: 19
Trade AMPH Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Jefferies analyst, David Steinberg, reiterated his Buy rating on shares of Amphastar Pharmaceuticals (NASDAQ: AMPH) and raised the price target to $21 after revs of $64M were $5M ahead of expectations and better than expected gross margin drove Q3 EPS out performance ($0.14 vs -$0.20 JEF).

Q3 revs benefited from higher than projected nonrecurring insulin API sales to MNKD and the analyst expects the approvals of Primatene and an undisclosed ANDA product as key to AMPH’s FY17 outlook.

The PT increased to $21 from $19 on 2.7x EV/S applied to FY17 revenue of $340M.

For an analyst ratings summary and ratings history on Amphastar Pharmaceuticals click here. For more ratings news on Amphastar Pharmaceuticals click here.

Shares of Amphastar Pharmaceuticals closed at $17.63 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change, Earnings

Related Entities

Jefferies & Co

Add Your Comment